
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
Keywords: ازتیمایب; Chronic kidney disease (CKD); cardiovascular disease risk; atherosclerotic events; LDL-cholesterol lowering; lipid lowering; cost-effectiveness; statin; ezetimibe; quality-adjusted life-year (QALY); health care costs;